Dynatrace Inc. (DT) PT Lowered to $68 at BofA Securities

BofA Securities analyst Koji Ikeda lowered the price target on Dynatrace Inc. (NYSE: DT) to $68.00 (from $70.00) while maintaining a Buy rating.

The analyst comments "Dynatrace (DT) reported good F4Q24 results that were above the Street on ARR, revenue, operating income, and free cash flow. Initial FY25 guidance for ARR growth was below the +17.5% y/y Street at +15-16% in constant currency (+14-15% reported), although this was anticipated. There are two factors driving the conservative outlook. One, an ongoing challenging macro. Two, consideration for changes in the sales organization (discussed below). The potential upside to near-term growth is up for debate. However, the F1Q24 results support our long-term bull thesis that it's taking share in the attractive enterprise DevSecOps opportunity. Reiterate Buy, $68 PO."

You May Also Be Interested In

• Incyte (INCY) PT Raised to $105 at Truist Securities
• Taysha Gene Therapies (TSHA) PT Raised to $10 at BofA Securities
• Definium Therapeutics Inc (DFTX) PT Raised to $52 at Leerink